Dr. Mikhail Blagosklonny’s Theory On Rapamycin’s Amazing Healing Properties
Dr. Mikhail Blagosklonny is a professor of Oncology in New York, at the Rosewell Park Cancer Institute. He earned an M.D. in internal medicine from the First Pavlov State Medical University of St. Petersburg. He got his Ph.D. in cardiology and experimental medicine from the same institution. He was appointed associate Prof. of medicine in 2002, at the New York Medical College, Valhalla, New York before taking the position of senior scientist at the Ordway Research Institute in Albany, New York. Mikhail held this position until he was appointed Prof. of oncology in 2009 (at Roswell Park Cancer Institute). Read Mikhail’s plans for Oncology on Healingmagic.net.
He has conducted a great amount of research on cancer treatment and its therapies. In his role as chief editor of Oncotarget, Mikhail has carried out and published extensive studies on aging. He is known for advocating Rapamycin as a drug for extending the lifespan of humans. Dr. Mikhail Blagosklonny’s contribution to this area is immense and unparalleled. He has formulated a hypothesis regarding the role of TOR in aging and cancer apart from proposing the use of Rapamycin, a popular drug for cancer treatment as a possible life extension mechanism. Below are reasons why Rapamycin is recommended for longevity according to Dr. Mikhail Blagosklonny’s hypothesis:
After organ transplantation, the primary reaction of the body is to reject the transplanted organ. When this happens, the transplantation fails. Hence, doctors will prescribe anti-rejection drugs (immunosuppressive drugs or calcineurin inhibitors). These drugs may adversely affect the kidneys over an extended period. However, Rapamycin scores well over other immunosuppressive drugs. Rapamycin displays lower toxicity levels towards the kidneys.
Treating Hemolytic-uremic Syndrome
A rare disease caused by a combination of kidney failure, anemia, and low platelet count. You can be on dialysis permanently. However, the best treatment is kidney transplantation. When you have kidneys transplanted, you will need to take calcineurin inhibitors. In such scenario, there is a strong chance that the new kidney can fail due to the same disease. Rapamycin reduces this probability greatly due to its low toxicity level towards kidneys.
The disease may sound frightening. However, the condition is usually not scary. The reason for this is that it is a rare lung disease that often affects women of childbearing age. It has been shown that Rapamycin is the leading drug that has been approved to treat this ailment. LAM infiltrates lung tissue with the TSC2 (Tuberous Sclerosis Complex gene) mutations ultimately activating the mTOR signaling pathway. This typically results in the development of Lymphangiogenic growth factors. Rapamycin is designed to blocks this gateway and stop Lymphangiogenic growth.
Coating The Coronary Stent
One of the primary applications of Rapamycin is coronary stent coating. This is done to halt the development of restenosis in a patient’s arteries following a balloon angioplasty procedure. Studies have found that patients who have undergone this treatment or used this coating show a lesser rate of the development of restenosis. The key benefit of using the Sirolimus coated stents is the fact that you will not need to repeat the procedure often. Read more on Impact Journals.